Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF) (2017 - 2025)

Dianthus Therapeutics has reported Depreciation & Amortization (CF) over the past 8 years, most recently at $27000.0 for Q3 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $27000.0 for Q3 2025, up 8.0% from a year ago — trailing twelve months through Sep 2025 was $110000.0 (up 22.22% YoY), and the annual figure for FY2024 was $96000.0, up 43.28%.
  • Depreciation & Amortization (CF) for Q3 2025 was $27000.0 at Dianthus Therapeutics, down from $30000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for DNTH hit a ceiling of $511000.0 in Q1 2022 and a floor of $18000.0 in Q3 2023.
  • Median Depreciation & Amortization (CF) over the past 4 years was $27000.0 (2025), compared with a mean of $181357.1.
  • Biggest five-year swings in Depreciation & Amortization (CF): tumbled 96.18% in 2023 and later soared 38.89% in 2024.
  • Dianthus Therapeutics' Depreciation & Amortization (CF) stood at $441000.0 in 2022, then plummeted by 95.46% to $20000.0 in 2023, then grew by 30.0% to $26000.0 in 2024, then grew by 3.85% to $27000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $27000.0 (Q3 2025), $30000.0 (Q2 2025), and $27000.0 (Q1 2025) per Business Quant data.